Clinical Trial: InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS

Brief Summary:

Gut dysbiosis is an intestinal disorder that is characterized by accumulation of microbiota imbalance, host-microbiota crosstalk dysfunction and inflammation.

As part of its clinical development, MaaT (Microbiota as a Therapy) Pharma is particularly interested in patients with Bone and Joint Infections (BJI). These patients are treated with antibiotics having significant consequences on their intestinal flora, causing intestinal discomfort, which can be manifested by diarrhea.

MaaT Pharma wishes to carry out a clinical study, OSIRIS, in collaboration with Prof. Tristan Ferry, member and coordinator of CRIOAc (Centre de Référence des Infections Ostéo-Articulaires Complexes) Lyon, Center of Reference of Bone and Joint Infections (BJI). The objective of this study is to follow patients with treated BJI in order to characterize intestinal dysbiosis and the future relevance of an autologous Fecal Microbiota Transplantation (aFMT) intervention.

To do this, patients will be monitored according to the current CRIOAc recommendations, with the aim of taking biological samples from patients at the same time as scheduled visits, routine monitoring patients. Only one additional consultation will be carried out 15 days after stopping the antibiotics in order to better evaluate the dysbiosis evolution.

Thus biological samples (blood, stool, nasal, rectal) will be taken during the follow-up consultations over a period of 6 months.


Detailed Summary:
Sponsor: MaaT Pharma

Current Primary Outcome: Evolution of intensity and frequency of Diarrheic Symptoms [ Time Frame: From baseline, up to 15 days after antibiotherapy treatment stop (Week 8 to week 14) ]

Assessment of the evolution of intensity and frequency of Diarrheic Symptoms from baseline, during antibiotic treatment (W2), at the end of treatment (W6-12) and 15 days after antibiotherapy treatment stop (W8-14)


Original Primary Outcome: Same as current

Current Secondary Outcome: Characterization of the gut dysbiosis and its prevalence in patients with BJI and under antibiotic treatment : measured by NGS (Next-Generation Sequencing) method [ Time Frame: Between baseline, after antibiotherapy treatment stop (Week 8-14) and the end of the follow-up (6 months) ]

Original Secondary Outcome: Same as current

Information By: MaaT Pharma

Dates:
Date Received: December 27, 2016
Date Started: December 2016
Date Completion: December 2017
Last Updated: April 21, 2017
Last Verified: April 2017